| Vol. 15.41 – 19 October, 2023 |
| |
|
|
| Researchers examined promyelocytic leukemia (PML) chromatin association in TNBC cell lines, where it exerted important oncogenic functions. [Nucleic Acids Research] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors showed that the DNA damage response in normal mammary gland inherently depended on the epithelial cell lineage identity. [Cell Reports] |
|
|
|
| Investigators showed that receptor for activated C kinase 1 (RACK1) was required for breast cancer cell proliferation in vitro and tumor growth in vivo. [Cell Death & Disease] |
|
|
|
| Researchers identified that proline synthetase PYCR1 was critical for breast cancer stemness and tumor growth. PYCR1-synthesized proline activated cGMP-PKG signaling to enhance cancer stem-like traits. [Cell Death & Disease] |
|
|
|
| Scientists identified KLHL29, which was an understudied member of the Kelch-like gene family, as a crucial tumor suppressor that regulates chemosensitivity in TNBC. [Oncogene] |
|
|
|
| The effects of Algae- silver nanoparticles synthesized were tested on MDA-MB-231 human breast cancer cells and HaCat human keratinocyte normal cells. [Biomedicine & Pharmacotherapy] |
|
|
|
| Researchers found that ε-Sarcoglycan (SGCE) depletion reduces breast cancer stem cells, partially through inhibiting the transcription of FGF-BP1, a secreted oncoprotein. [Journal of Biological Chemistry] |
|
|
|
| Scientists shed light on the reciprocal relationship between cystathionine-β-synthase and cystathionine-γ-lyase and on the importance of their dual targeting, particularly in TNBC. [Heliyon] |
|
|
|
| The investigators elucidated the biological role of circAGFG1 in breast cancer and explored its potential downstream molecular mechanisms. [Acta Biochimica Polonica] |
|
|
|
|
| The authors summarize the current understanding of breast cancer stem cells, their biomarkers, and the associated signaling pathways. [Critical Reviews in Oncology/Hematology] |
|
|
|
|
| The charity Breast Cancer Now has awarded £249,992 to Dr. Sankari Nagarajan and her team at The University of Manchester to help discover why some TNBCs spread to other parts of the body and whether existing drugs can be repurposed to stop this. [Manchester Cancer Research Centre] |
|
|
|
|
| November 28 – 30, 2023 Philadelphia, Pennsylvania, United States |
|
|
|
|
|
| University of Gothenburg – Gothenburg, Sweden |
|
|
|
| University of Alabama at Birmingham – Birmingham, Alabama, United States |
|
|
|
| NYU Medical Center – New York, New York, United States |
|
|
|
| Stanford University – Stanford, California, United States |
|
|
|
| UmeÃ¥ University – UmeÃ¥, Sweden |
|
|
|
|